NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

marzan, the majority of the 100 alive in June were PFS. Around 12/16 or 1/17 there were around 83 PFS. Based on the death rate of 2 per month since June I am assuming an equal rate of about 2 progressions per months from 12/16 or 1/17. In June we would have therefore ended up with about 71-73 PFS among the 100 survivors. Even if a few patients were lost (LTFU) the PFS constitute a clear majority among the 100 alive.

This would not prove that PFS was a success since we don't know whether the difference between controls and trial was SS but it does show that a very large proportion of the patients (maybe a subtype(s)?) had delayed progression and an extended survival and it would strongly suggest that DCVax-L was responsible.